Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Fired CDC chief will testify Kennedy pressed her to endorse vaccine recommendations without evidence — REUTERS / pwu404

CDC · Washington

Fired CDC chief will testify Kennedy pressed her to endorse vaccine recommendations without evidence

57% Center coverage: 233 sources

Fired Centers for Disease Control and Prevention director Susan Monarez will tell senators that Health Secretary Robert F. Kennedy Jr. pressured her to endorse new vaccine recommendations before seeing scientific evidence, according to a copy of the testimony she plans to give during a Wednesday hearing.See the Story

GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years

Donald Trump · United States

GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years

47% Center coverage: 17 sources

President Trump has been pursuing policies intended to entice drugmakers to bring manufacturing and jobs to the U.S. GSK’s announcement makes it the latest big pharma company to unveil a multi-billion dollar plan for new U.S. facilities. The post GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years appeared first on MedCity News.See the Story

Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs

Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs

100% Center coverage: 4 sources

Novartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.See the Story

Breaking News Topics Related to biopharmadive.com